Toboroz
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
NCT07775924· 2. fázis· Novartis Pharmaceuticals· Forrás
Még nem toboroz
A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2026-526184-38-00· 2. fázis· Enveda Therapeutics Inc.· Forrás
Toboroz
A Phase 2b Study of the Effects of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis
2026-525673-39-00· 2. fázis· Apollo Therapeutics Limited· Forrás
Toboroz
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa
NCT07547813· 2. fázis· Almirall, S.A.· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263· 2. fázis· Takeda· Forrás
Fut, nem toboroz
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
NCT07223697· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
NCT07384975· 2. fázis· Navigator Medicines, Inc.· Forrás
Fut, nem toboroz
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660· 2. fázis· UCB Biopharma SRL· Forrás
Toboroz
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015· 2. fázis· Kymera Therapeutics, Inc.· Forrás
Fut, nem toboroz
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT07228390· 2. fázis· Pfizer· Forrás
Fut, nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT07029828· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· 2. fázis· Inmagene LLC· Forrás
Fut, nem toboroz
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
2024-515672-12-00· 3. fázis· Sun Pharmaceutical Industries Limited· Forrás
Toboroz
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Fut, nem toboroz
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228· 3. fázis· AbbVie· Forrás
Toboroz
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682· 3. fázis· LEO Pharma· Forrás
Még nem toboroz
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated with Dupilumab.
NCT05694884· 2. fázis· Aslan Pharmaceuticals Pte Ltd· Forrás
Toboroz
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
2023-505121-14-00· 3. fázis· Janssen - Cilag International· Forrás
Fut, nem toboroz
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Plaque Psoriasis Involving Special Areas
2023-505122-34-00· 3. fázis· Janssen - Cilag International· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741· 2. fázis· Nektar Therapeutics· Forrás
Leállították
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198· 3. fázis· Eli Lilly and Company· Forrás